How to Prepare for Upcoming ISO 10993 Biocompatibility Updates (2025-2026)

## How to Prepare for Upcoming ISO 10993 Biocompatibility Updates (2025-2026) With the medical device industry anticipating significant revisions to the ISO 10993 series of biocompatibility standards around 2025-2026, manufacturers face a critical need to adapt their biological evaluation strategies. These updates are expected to continue the shift away from a simple checklist of in vivo tests and toward a more integrated, risk-based approach grounded in comprehensive material and chemical characterization. For sponsors of both new and legacy devices, preparing for this evolution is not just a matter of compliance, but a strategic imperative to ensure continued market access and patient safety. A forward-looking biological evaluation plan must now be a holistic process, beginning with a deep understanding of device materials and manufacturing processes. This approach uses analytical chemistry and toxicological risk assessment to build a robust safety profile, potentially reducing the reliance on traditional animal testing. By proactively aligning with these emerging principles, manufacturers can de-risk their regulatory submissions, optimize testing timelines, and build a more defensible biological safety case that will stand up to future scrutiny from regulatory bodies like the FDA. ### Key Points * **Shift from Testing to Risk Assessment:** The core evolution in ISO 10993 is the move from a default "checklist" of biological tests to a comprehensive biological risk assessment. The goal is to first understand the materials and potential leachables, and then determine what testing, if any, is needed to address remaining risks. * **Chemical Characterization is Foundational:** Enhanced chemical characterization (ISO 10993-18) is becoming the cornerstone of modern biocompatibility. Thorough extractables and leachables (E&L) analysis is critical for identifying and quantifying substances that could contact the body. * **Toxicological Risk Assessment Justifies Testing:** The data from chemical characterization feeds directly into a toxicological risk assessment (TRA) per ISO 10993-17. A robust TRA can be used to demonstrate that identified leachables are present at safe levels, providing a powerful justification for waiving certain in vivo tests. * **Proactive Gap Analysis for Legacy Devices:** Manufacturers should not assume that existing biocompatibility data for marketed devices will remain sufficient. Changes in suppliers, manufacturing processes, or the standards themselves should trigger a formal gap analysis to identify and address any new requirements. * **Early FDA Engagement is Crucial:** For novel devices or complex testing strategies, the FDA Q-Submission program is an invaluable tool. It allows sponsors to gain alignment with the agency on a proposed Biological Evaluation Plan (BEP) *before* committing significant resources to testing. ### The Evolving Landscape: From Test Checklists to a Holistic Risk Management Process Historically, demonstrating biocompatibility often followed a prescriptive path outlined in the annex of ISO 10993-1. A device was categorized by its contact type and duration, and a corresponding set of standard biological tests (e.g., cytotoxicity, sensitization, irritation) was performed. While straightforward, this "checklist" approach did not always account for the specific materials, processing residues, or clinical use of a device. The anticipated updates continue to formalize a more scientific, risk-based framework. This modern approach is a continuous cycle, often described as follows: 1. **Biological Evaluation Plan (BEP):** This initial phase involves gathering all existing information about the device's materials, manufacturing, intended use, and patient contact. The goal is to perform an initial risk assessment and create a documented plan that outlines the strategy to address all potential biological hazards. 2. **Data Gathering and Risk Assessment:** This is the core "doing" phase. It involves executing the plan, which increasingly emphasizes chemical characterization and toxicological risk assessment *before* considering biological tests. If chemical data and a TRA can sufficiently address a potential risk (e.g., systemic toxicity), a traditional in vivo test may not be necessary. 3. **Biological Evaluation Report (BER):** This final report synthesizes all the data—material information, E&L results, toxicological assessments, and any biological testing performed—to draw a final conclusion about the biological safety of the device. The BER is not just a summary of test results; it is the comprehensive argument for why the device is safe for its intended use. This evolution aligns with the globally accepted "3Rs" principle of animal testing: **Replace, Reduce, and Refine**. By leveraging advanced analytical chemistry and toxicology, the new paradigm aims to reduce the number of animals used in testing by ensuring that in vivo studies are only performed when a specific risk cannot be addressed through other means. ### The Central Role of Chemical Characterization and Toxicological Assessment For complex devices, particularly long-term implants like a novel cardiovascular stent or an implantable glucose sensor, the emphasis on chemistry is paramount. A forward-looking strategy involves treating chemical characterization not as an optional step, but as the foundational evidence for the entire biological evaluation. #### What a Robust Chemical Characterization Study Involves Under ISO 10993-18, a chemical characterization study is designed to identify and quantify substances that may be released from a device during its clinical use. A robust study that can withstand regulatory scrutiny typically includes: * **Exaggerated or Exhaustive Extractions:** The device is exposed to various solvents under aggressive conditions (e.g., elevated temperature, extended time) to simulate worst-case clinical exposure and extract the maximum amount of potential leachables. * **Multiple Advanced Analytical Techniques:** A suite of highly sensitive analytical methods is used to detect a wide range of organic and inorganic substances. Common techniques include Gas Chromatography-Mass Spectrometry (GC-MS), Liquid Chromatography-Mass Spectrometry (LC-MS), and Inductively Coupled Plasma-Mass Spectrometry (ICP-MS). * **A Low Analytical Evaluation Threshold (AET):** The AET is the threshold at which a detected substance must be identified and quantified. A lower AET means the study is more sensitive and less likely to miss potentially harmful compounds, which is a key expectation from regulators. #### Connecting Chemistry to Safety: The Toxicological Risk Assessment (TRA) The list of compounds generated from the E&L study is meaningless without interpretation. This is the purpose of the TRA, conducted according to ISO 10993-17. A qualified toxicologist evaluates each identified leachable to determine its potential health risk. This involves: 1. **Hazard Identification:** Reviewing scientific literature to understand the toxicological profile of each compound. 2. **Dose-Response Assessment:** Establishing a Tolerable Intake (TI) level for each compound, which is the maximum daily dose considered safe. 3. **Exposure Assessment:** Calculating the worst-case patient exposure to the compound based on the E&L data. 4. **Risk Characterization:** Comparing the calculated patient exposure to the safe threshold (TI). If the exposure is well below the safe level, a Margin of Safety (MOS) is established, and the risk is considered acceptable. For a long-term implantable sensor, a robust E&L study combined with a comprehensive TRA could provide sufficient evidence to argue that long-term systemic toxicity studies in animals are not required. This justification, however, must be exceptionally well-documented in the BER. ### Strategic Planning for Legacy Devices: When to Re-Evaluate Manufacturers of devices already on the market cannot afford to be complacent. The introduction of updated standards creates a new benchmark for safety, and regulators may expect legacy device submissions (e.g., for significant changes) to meet the current consensus standards. A proactive gap analysis is essential. **Key triggers that should prompt a re-evaluation of biocompatibility for a legacy device include:** * **Material or Supplier Change:** Any change to a patient-contacting material, colorant, adhesive, or even a supplier of a raw material can alter the device's chemical profile and warrants a risk assessment. * **Manufacturing or Sterilization Process Change:** Modifications to processes like molding, cleaning, packaging, or sterilization (e.g., switching from EtO to gamma) can introduce new process residues or alter material properties, requiring re-evaluation. * **Changes in Intended Use:** Expanding the use of a device to a new patient population, a longer duration of contact, or a different part of the body will almost always require a new biological evaluation. * **Post-Market Surveillance Data:** Any unexpected adverse events or biological reactions reported from the field should immediately trigger a review of the biological risk assessment. * **Updates to Regulatory Standards:** The publication of revised ISO 10993 standards is itself a trigger. A gap analysis should be performed to compare the original testing data against the new requirements and document why the existing data is still sufficient or identify what new data is needed. The output of this analysis should be a formal report that is maintained in the device's technical documentation or design history file. ### Strategic Considerations and the Role of Q-Submission When a manufacturer's proposed biological evaluation strategy deviates from the well-trodden path—for instance, by proposing to waive multiple in vivo tests for a novel implant based on chemical characterization—it carries inherent regulatory risk. The FDA's Q-Submission program is the primary tool for mitigating this risk. A Q-Submission (or Pre-Submission) allows a sponsor to present its proposed testing plan to the FDA and receive feedback before beginning costly and time-consuming studies. For biocompatibility, a Q-Sub is particularly valuable in the following scenarios: * **Novel Materials:** When using a material with little or no history of use in medical devices. * **Justifying Waived Tests:** When planning to use E&L and TRA data to justify forgoing standard biological tests, especially for long-term implants. * **Complex Devices:** For devices with multiple material components, borderline contact duration, or unique clinical applications where standard testing paradigms may not apply. * **Bridging to Existing Data:** When seeking to leverage biocompatibility data from a similar predicate or family device to reduce the testing burden for a new device. A successful Q-Sub package for biocompatibility should include a detailed Biological Evaluation Plan (BEP), a clear rationale for the proposed strategy, specific questions for the FDA, and all supporting data available to date. Gaining the FDA's agreement on the plan provides a significant level of confidence that the strategy will be acceptable in the final marketing submission. ### Finding and Comparing Biocompatibility Testing Services Providers Selecting the right contract research organization (CRO) or testing lab is as critical as the plan itself. A strong partner acts as a strategic advisor, not just a service provider. When evaluating potential labs, manufacturers should look for: * **ISO/IEC 17025 Accreditation:** This is the baseline quality standard for testing and calibration laboratories. * **Integrated Expertise:** The ideal lab has deep expertise across all necessary disciplines: analytical chemistry (for E&L), toxicology (for TRA), and traditional biology/pathology (for in vivo testing). * **Regulatory Experience:** The provider should have a proven track record of submitting biocompatibility data to the FDA and other global regulatory bodies. Ask about their experience with Q-Submissions and their success rate. * **Device-Specific Knowledge:** A lab that specializes in orthopedic implants will have different insights than one focused on IVDs. Look for experience with your specific device type, materials, and manufacturing processes. * **Collaborative Approach:** A good partner will work with you to optimize the testing plan, helping to build a scientifically sound rationale for your strategy rather than simply recommending a standard battery of tests. Comparing providers on more than just price is essential. A cheaper quote for a poorly designed study will cost far more in the long run if it leads to regulatory delays or the need for repeat testing. > To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free. ### Key FDA References When developing a biological evaluation strategy for a US submission, it is critical to consult the latest FDA guidance documents in addition to the ISO 10993 standards. Sponsors should always refer to the FDA website for the most current versions. * **FDA Guidance on the Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process"** * **FDA's Q-Submission Program Guidance** * **General device regulations under 21 CFR, including quality system regulations (Part 820)** --- This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*